KRAS strikes back
First-in-human trial initiations reveal four KRAS assets.
First-in-human trial initiations reveal four KRAS assets.
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
First-in-human clinical trial listings include AZD0754, Astra’s internally developed Car-T therapy.
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.